Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Effect of non-invasive vagus nerve stimulation in hemorrhagic brain injury and permanent ischemic stroke in rats
Cerebrovascular Disease and Interventional Neurology
P10 - Poster Session 10 (8:00 AM-9:00 AM)
13-005
nVNS has been shown to reduce infarct volume after transient ischemia in rats.
This study evaluated the effects of non-invasive vagus nerve stimulation (nVNS) on intracerebral hemorrhage (ICH) and permanent ischemic brain injury models.

ICH was induced by whole blood (n=24) or collagenase (n=24) injection into the striatum of adult male and female Wistar rats. One-hour sham stimulation (n=16) or nVNS (n=32) was initiated 30 minutes after injection. Spontaneous circling, hindlimb retraction, and grasp ability were tested at 24 hours to measure functional deficit. Rats were euthanized 24 hours or 1 week after injury, and brain tissue was processed for water content analysis (n=24) and histology (n=24), respectively.

Permanent ischemia was induced by filament occlusion of the right middle cerebral artery in adult male Wistar rats (n=18). Sham stimulation or nVNS were initiated 30 minutes after the induction of ischemia and were applied for either 1 hour (sham or nVNS) or 3 hours (nVNS) (n=6 per group). Rats were euthanized 24 hours later to measure infarct volume.

Animals treated with nVNS demonstrated better functional outcome at 24 hours after ICH (p=0.042 vs sham). One-hour nVNS was associated with a nonsignificant reduction in hematoma volume in both models of ICH. There was no difference in brain edema between sham and nVNS in either model of ICH. Three-hour nVNS reduced infarct volume by 21% in permanent ischemia (p=0.047 vs sham). 
These results support prior evidence that nVNS may be a viable acute stroke treatment. nVNS is currently being evaluated in 2 clinical studies (NCT03733431 and NCT04050501) for the treatment of acute ischemic stroke. The lack of adverse outcomes in 2 different models of ICH in this study suggests that nVNS could be safely administered before the stroke etiology (ischemic vs hemorrhagic) has been determined.
Authors/Disclosures

PRESENTER
No disclosure on file
Eric J. Liebler (ElectroCore LLC) Eric J. Liebler has received personal compensation for serving as an employee of electroCore. Eric J. Liebler has received stock or an ownership interest from electroCore.
No disclosure on file